A Two-part, Single-center, Single-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Four-way Crossover Study to Investigate the Effect of RO7033877 on the QT/QTc Interval in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Sep 2015
At a glance
- Drugs RO 7033877 (Primary) ; Moxifloxacin
- Indications Unspecified
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Roche
- 23 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Nov 2014 Planned number of patients changed from 80 to 112 as reported by ClinicalTrials.gov.
- 03 Nov 2014 Planned End Date changed from 1 Oct 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.